Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Nov 12, 2014; 4(4): 113-123
Published online Nov 12, 2014. doi: 10.5318/wjo.v4.i4.113
What is new in central serous chorioretinopathy?
Michal Schaap-Fogler, Rita Ehrlich
Michal Schaap-Fogler, Rita Ehrlich, Department of Ophthalmology, Rabin Medical Center, Petach Tikva 49100, Israel
Author contributions: Schaap-Fogler M and Ehrlich R both contributed to this paper, including: (1) substantial contributions to conception and design, acquisition of data and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the version to be published.
Correspondence to: Michal Schaap-Fogler, MD, Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, 39 Zabotinski Street, Petach Tikva 49100, Israel. fogler@gmail.com
Telephone: +972-39-376107 Fax: +972-39-376104
Received: May 29, 2014
Revised: July 5, 2014
Accepted: September 4, 2014
Published online: November 12, 2014
Processing time: 169 Days and 10.9 Hours
Core Tip

Core tip: (1) New diagnostic tools and therapies may improve the prognosis of patients with chronic or recurrent central serous chorioretinopathy; (2) Changes in fundus autoflouresence images help differentiate an active disease from an inactive state; (3) Multifocal electroretinography and macular microperimetry may serve as follow up tools due to their ability to measure macular visual function; (4) Focal argon laser photocoagulation shortens disease duration but does not affect final prognosis; (5) Reduced-fluence photodynamic therapy improves visual acuity and resolves serous detachments; and (6) The role of anti-vascular endothelial growth factor agents, micropulse diode laser, corticosteroid antagonists, aspirin, anti-viral or Helicobacter pylori treatment is still being investigated.